FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943928304> ?p ?o ?g. }

• W2943928304 abstract "Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor. ExteNET, a randomized placebo-controlled phase III study, showed that neratinib given for 12 months after trastuzumab-based adjuvant therapy significantly improved 2-year (HR 0.67; 95% CI 0.50–0.91; p=0.0091) and 5-year (HR 0.73; 95% CI 0.57-0.92; p=0.008) iDFS in pts with early-stage HER2+ breast cancer. Anti-diarrheal prophylaxis was not mandated by protocol; grade 3/4 diarrhea occurred in 40% of pts with a median cumulative duration of 5 days. The phase II CONTROL study was initiated to investigate the effectiveness of various prophylactic regimens in the prevention of neratinib-associated diarrhea. Loperamide (L) alone or in combination with add-on agents targeting underlying inflammation [i.e. budesonide (BUD)] or bile acid malabsorption [i.e. colestipol (COL)] were tested. We report longitudinal HRQoL findings from both ExteNET and CONTROL. Methods: Pts with early-stage HER2+ breast cancer who had received trastuzumab-based adjuvant therapy were eligible for both studies. In ExteNET, pts received neratinib or placebo for 12 months. In CONTROL, pts received neratinib for 13 x 28-day cycles combined with L, L + BUD or L + COL for 1 or 2 cycles (see table for schedules). HRQoL was assessed using Functional Assessment of Cancer Therapy–Breast (FACT-B), v4.0, at baseline, months 1, 3, 6, 9, 12 (ExteNET) or baseline, cycles 2, 4, 7, 10, 13 (CONTROL). Changes in scores from baseline were considered to be clinically meaningful if greater than the lowest estimate for an 9important difference9 (ID) reported in the literature. Evaluable pts were required to have HRQoL assessments at baseline and at least 1 post-baseline. ClinicalTrials.gov: NCT00878709 (ExteNET); NCT02400476 (CONTROL). Results: HRQoL findings are summarized in the table. Hospitalization rates due to diarrhea: 1.5% (neratinib + L), 0% (other cohorts) in CONTROL; and 1.4% (neratinib), 0.1% (placebo) in ExteNET. Conclusions: Adjuvant neratinib with or without anti-diarrheal prophylaxis was associated with small decreases in HRQoL. With the exception of the FACT-B PWB subscale, HRQoL changes did not reach clinically meaningful thresholds. Follow-up in CONTROL is ongoing. Citation Format: Delaloge S, Hurvitz S, Chan N, Bose R, Jankowitz RC, Thirlwell M, Lang I, ten Tije A, Trudeau M, Osborne CR, Shen Z-Z, Lalla D, Xu F, Hunt D, Olek E, Tripathy D, Rugo HS, Chien J, Chan A, Barcenas CH. The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in HER2+ early-stage breast cancer: Analyses from the ExteNET and CONTROL trials [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-13-03." @default.
• W2943928304 created "2019-05-16" @default.
• W2943928304 creator A5001373717 @default.
• W2943928304 creator A5007327429 @default.
• W2943928304 creator A5009477344 @default.
• W2943928304 creator A5011287285 @default.
• W2943928304 creator A5016372539 @default.
• W2943928304 creator A5017183298 @default.
• W2943928304 creator A5021913157 @default.
• W2943928304 creator A5023674071 @default.
• W2943928304 creator A5026987682 @default.
• W2943928304 creator A5030138461 @default.
• W2943928304 creator A5034362951 @default.
• W2943928304 creator A5034773412 @default.
• W2943928304 creator A5049358292 @default.
• W2943928304 creator A5058510337 @default.
• W2943928304 creator A5067455288 @default.
• W2943928304 creator A5071886988 @default.
• W2943928304 creator A5072015843 @default.
• W2943928304 creator A5073839596 @default.
• W2943928304 creator A5081886321 @default.
• W2943928304 creator A5090714331 @default.
• W2943928304 date "2019-02-15" @default.
• W2943928304 modified "2023-10-14" @default.
• W2943928304 title "Abstract P2-13-03: The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in HER2+ early-stage breast cancer: Analyses from the ExteNET and CONTROL trials" @default.
• W2943928304 doi "https://doi.org/10.1158/1538-7445.sabcs18-p2-13-03" @default.
• W2943928304 hasPublicationYear "2019" @default.
• W2943928304 type Work @default.
• W2943928304 sameAs 2943928304 @default.
• W2943928304 citedByCount "0" @default.
• W2943928304 crossrefType "proceedings-article" @default.
• W2943928304 hasAuthorship W2943928304A5001373717 @default.
• W2943928304 hasAuthorship W2943928304A5007327429 @default.
• W2943928304 hasAuthorship W2943928304A5009477344 @default.
• W2943928304 hasAuthorship W2943928304A5011287285 @default.
• W2943928304 hasAuthorship W2943928304A5016372539 @default.
• W2943928304 hasAuthorship W2943928304A5017183298 @default.
• W2943928304 hasAuthorship W2943928304A5021913157 @default.
• W2943928304 hasAuthorship W2943928304A5023674071 @default.
• W2943928304 hasAuthorship W2943928304A5026987682 @default.
• W2943928304 hasAuthorship W2943928304A5030138461 @default.
• W2943928304 hasAuthorship W2943928304A5034362951 @default.
• W2943928304 hasAuthorship W2943928304A5034773412 @default.
• W2943928304 hasAuthorship W2943928304A5049358292 @default.
• W2943928304 hasAuthorship W2943928304A5058510337 @default.
• W2943928304 hasAuthorship W2943928304A5067455288 @default.
• W2943928304 hasAuthorship W2943928304A5071886988 @default.
• W2943928304 hasAuthorship W2943928304A5072015843 @default.
• W2943928304 hasAuthorship W2943928304A5073839596 @default.
• W2943928304 hasAuthorship W2943928304A5081886321 @default.
• W2943928304 hasAuthorship W2943928304A5090714331 @default.
• W2943928304 hasConcept C121608353 @default.
• W2943928304 hasConcept C126322002 @default.
• W2943928304 hasConcept C142724271 @default.
• W2943928304 hasConcept C143998085 @default.
• W2943928304 hasConcept C204787440 @default.
• W2943928304 hasConcept C27081682 @default.
• W2943928304 hasConcept C2779413316 @default.
• W2943928304 hasConcept C2779786085 @default.
• W2943928304 hasConcept C2779802037 @default.
• W2943928304 hasConcept C530470458 @default.
• W2943928304 hasConcept C71924100 @default.
• W2943928304 hasConcept C90924648 @default.
• W2943928304 hasConceptScore W2943928304C121608353 @default.
• W2943928304 hasConceptScore W2943928304C126322002 @default.
• W2943928304 hasConceptScore W2943928304C142724271 @default.
• W2943928304 hasConceptScore W2943928304C143998085 @default.
• W2943928304 hasConceptScore W2943928304C204787440 @default.
• W2943928304 hasConceptScore W2943928304C27081682 @default.
• W2943928304 hasConceptScore W2943928304C2779413316 @default.
• W2943928304 hasConceptScore W2943928304C2779786085 @default.
• W2943928304 hasConceptScore W2943928304C2779802037 @default.
• W2943928304 hasConceptScore W2943928304C530470458 @default.
• W2943928304 hasConceptScore W2943928304C71924100 @default.
• W2943928304 hasConceptScore W2943928304C90924648 @default.
• W2943928304 hasLocation W29439283041 @default.
• W2943928304 hasOpenAccess W2943928304 @default.
• W2943928304 hasPrimaryLocation W29439283041 @default.
• W2943928304 hasRelatedWork W1935794 @default.
• W2943928304 hasRelatedWork W2002252610 @default.
• W2943928304 hasRelatedWork W2045679496 @default.
• W2943928304 hasRelatedWork W2061070172 @default.
• W2943928304 hasRelatedWork W2134161787 @default.
• W2943928304 hasRelatedWork W2155966588 @default.
• W2943928304 hasRelatedWork W2807514642 @default.
• W2943928304 hasRelatedWork W3031664910 @default.
• W2943928304 hasRelatedWork W3060503053 @default.
• W2943928304 hasRelatedWork W4206490280 @default.
• W2943928304 isParatext "false" @default.
• W2943928304 isRetracted "false" @default.
• W2943928304 magId "2943928304" @default.
• W2943928304 workType "article" @default.